Related Experiment Videos
Primary hyperparathyroidism and parathyroid hormone-related protein
1Columbia University, New York, New York.
Current Opinion in Rheumatology
|May 1, 1994
Summary
Primary hyperparathyroidism and malignancy-related hypercalcemia are common. Parathyroid hormone-related protein (PTHrP) plays a key role in malignancy-induced hypercalcemia, differentiating it from primary hyperparathyroidism.
Area of Science:
- Endocrinology
- Oncology
- Bone Metabolism
Background:
- Hypercalcemia is frequently linked to primary hyperparathyroidism and malignancy.
- Malignancy-associated hypercalcemia is often caused by parathyroid hormone-related protein (PTHrP).
- Primary hyperparathyroidism typically presents asymptomatically in modern clinical practice.
Purpose of the Study:
- To differentiate between hypercalcemia causes, specifically primary hyperparathyroidism and malignancy.
- To highlight the role of PTHrP in malignancy-induced hypercalcemia.
- To discuss diagnostic approaches and management guidelines for hypercalcemia.
Main Methods:
- Utilizing diagnostic tools like bone mineral densitometry and bone histomorphometry.
- Employing immunoradiometric assays for parathyroid hormone (PTH) levels.
- Measuring PTHrP levels in patients with hypercalcemia.
Main Results:
- Primary hyperparathyroidism is characterized by excessive PTH secretion.
- Hypercalcemia of malignancy can often be identified by the presence of a tumor and suppressed PTH levels.
- Elevated PTHrP levels are observed in malignancy-associated hypercalcemia.
Conclusions:
- PTHrP is a significant factor in malignancy-induced hypercalcemia.
- Distinguishing hypercalcemia of malignancy from primary hyperparathyroidism is crucial for appropriate management.
- Further research into the ubiquitous role of PTHrP in normal physiology is warranted.